Switch theme
Sign up to access all valuation multiples
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy; ES2B-I002, a Cytomegalovirus (CMV) vaccine; and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
2015
19
LTM Revenue $0.9M
Last FY EBITDA -$4.5M
$1.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ExpreS2ion Biotech Hldg has a last 12-month revenue (LTM) of $0.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, ExpreS2ion Biotech Hldg achieved revenue of $0.3M and an EBITDA of -$4.5M.
ExpreS2ion Biotech Hldg expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ExpreS2ion Biotech Hldg valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.9M | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | -$0.3M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | -89% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$4.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1400% | XXX | XXX | XXX |
| EBIT | -$6.6M | XXX | -$7.2M | XXX | XXX | XXX |
| EBIT Margin | -757% | XXX | -2247% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$3.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -1196% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, ExpreS2ion Biotech Hldg's stock price is SEK 26 (or $3).
ExpreS2ion Biotech Hldg has current market cap of SEK 69.4M (or $7.3M), and EV of SEK 11.7M (or $1.2M).
See ExpreS2ion Biotech Hldg trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2M | $7.3M | XXX | XXX | XXX | XXX | $-2.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, ExpreS2ion Biotech Hldg has market cap of $7.3M and EV of $1.2M.
ExpreS2ion Biotech Hldg's trades at 3.9x EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate ExpreS2ion Biotech Hldg's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ExpreS2ion Biotech Hldg's P/E ratio is not available.
See valuation multiples for ExpreS2ion Biotech Hldg and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.3M | XXX | $7.3M | XXX | XXX | XXX |
| EV (current) | $1.2M | XXX | $1.2M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -1.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialExpreS2ion Biotech Hldg's last 12 month revenue growth is 6%
ExpreS2ion Biotech Hldg's revenue per employee in the last FY averaged $17K, while opex per employee averaged $0.4M for the same period.
ExpreS2ion Biotech Hldg's rule of 40 is -1382% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ExpreS2ion Biotech Hldg's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ExpreS2ion Biotech Hldg and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 73% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1400% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1382% | XXX | -1394% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $17K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 885% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2158% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ExpreS2ion Biotech Hldg acquired XXX companies to date.
Last acquisition by ExpreS2ion Biotech Hldg was XXXXXXXX, XXXXX XXXXX XXXXXX . ExpreS2ion Biotech Hldg acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ExpreS2ion Biotech Hldg founded? | ExpreS2ion Biotech Hldg was founded in 2015. |
| Where is ExpreS2ion Biotech Hldg headquartered? | ExpreS2ion Biotech Hldg is headquartered in Sweden. |
| How many employees does ExpreS2ion Biotech Hldg have? | As of today, ExpreS2ion Biotech Hldg has 19 employees. |
| Who is the CEO of ExpreS2ion Biotech Hldg? | ExpreS2ion Biotech Hldg's CEO is Mr. Bent U. Frandsen. |
| Is ExpreS2ion Biotech Hldg publicy listed? | Yes, ExpreS2ion Biotech Hldg is a public company listed on STO. |
| What is the stock symbol of ExpreS2ion Biotech Hldg? | ExpreS2ion Biotech Hldg trades under EXPRS2 ticker. |
| When did ExpreS2ion Biotech Hldg go public? | ExpreS2ion Biotech Hldg went public in 2016. |
| Who are competitors of ExpreS2ion Biotech Hldg? | Similar companies to ExpreS2ion Biotech Hldg include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ExpreS2ion Biotech Hldg? | ExpreS2ion Biotech Hldg's current market cap is $7.3M |
| What is the current revenue of ExpreS2ion Biotech Hldg? | ExpreS2ion Biotech Hldg's last 12 months revenue is $0.9M. |
| What is the current revenue growth of ExpreS2ion Biotech Hldg? | ExpreS2ion Biotech Hldg revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of ExpreS2ion Biotech Hldg? | Current revenue multiple of ExpreS2ion Biotech Hldg is 1.4x. |
| Is ExpreS2ion Biotech Hldg profitable? | Yes, ExpreS2ion Biotech Hldg is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
